Journal of Chinese Integrative Medicine ›› 2011, Vol. 9 ›› Issue (1): 38-48.doi: 10.3736/jcim20110108
• Original Experimental Research • Previous Articles Next Articles
Ming-wei Huang, Huan Wang, Wen-juan Zhong, Xiao-ying Wu, Hui Chen(
)
| [1] |
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J]. N Engl J Med, 2002,346(23):1773-1780
doi: 10.1056/NEJMoa012843 |
| [2] |
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR , O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J]. N Engl J Med, 2003,349(14):1315-1323
doi: 10.1056/NEJMoa035071 |
| [3] |
Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD . Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious[J]. Circulation, 2004,109(6):701-705
doi: 10.1161/01.CIR.0000116202.41966.D4 |
| [4] |
Camenzind E, Steg PG, Wijns W . Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern[J]. Circulation, 2007,115(11):1440-1455
doi: 10.1161/CIRCULATIONAHA.106.666800 |
| [5] |
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G , Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW.Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study[J]. Lancet, 2007,369(9562):667-678
doi: 10.1016/S0140-6736(07)60314-6 |
| [6] |
Wenaweser P, Daemen J , Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S.Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study[J]. J Am Coll Cardiol, 2008,52(14):1134-1140
doi: 10.1016/j.jacc.2008.07.006 |
| [7] |
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001,345(7):494-502
doi: 10.1056/NEJMoa010746 |
| [8] |
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet, 2001,358(9281):527-533
doi: 10.1016/S0140-6736(01)05701-4 |
| [9] |
Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A . High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients[J]. Am J Cardiovasc Drugs, 2010,10(1):29-35
doi: 10.2165/11318260-000000000-00000 |
| [10] |
Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J , Schömig A, von Beckerath N, Kastrati A.Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement[J]. J Thromb Haemost, 2010,8(2):250-256
doi: 10.1111/jth.2010.8.issue-2 |
| [11] |
Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonzalez MA, Gaglia MA Jr, Xue Z, Kaneshige K, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R . Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents[J]. Am Heart J, 2010,159(5):871-875
doi: 10.1016/j.ahj.2010.01.016 |
| [12] |
Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, Chan E, Bousser MG, Xuemin S.Danqi Piantang Jiaonang ( DJ), a traditional Chinese medicine, in poststroke recovery[J]. Stroke, 2009,40(3):859-863
doi: 10.1161/STROKEAHA.108.531616 |
| [13] | Chen DK, Zhang HQ, Zhang JH . Intervening effect of Naoxintong on anti-platelet treatment with aspirin[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008,28(9):843-846 |
| 陈达开, 张怀勤, 张建华 . 脑心通对阿司匹林抗血小板治疗的干预作用[J]. 中国中西医结合杂志, 2008,28(9):843-846 | |
| [14] |
World Medical Association, American Physiological Society . Guiding principles for research involving animals and human beings[J]. Am J Physiol Regul Integr Comp Physiol, 2002,283(2):R281-R283
doi: 10.1152/ajpregu.00279.2002 |
| [15] |
Kudo M, Aoyama A, Ichimori S, Fukunaga N . An animal model of cerebral infarction. Homologous blood clot emboli in rats[J]. Stroke, 1982,13(4):505-508
doi: 10.1161/01.STR.13.4.505 |
| [16] |
Li S, Zhong S, Zeng K, Luo Y, Zhang F, Sun X, Chen L . Blockade of NF-κB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats[J]. Basic Res Cardiol, 2010,105(1):139-150
doi: 10.1007/s00395-009-0067-6 |
| [17] |
Erbel R, Heusch G . Coronary microembolization[J]. J Am Coll Cardiol, 2000,36(1):22-24
doi: 10.1016/S0735-1097(00)00708-7 |
| [18] |
Topol EJ, Yadav JS . Recognition of the importance of embolization in atherosclerotic vascular disease[J]. Circulation, 2000,101(5):570-580
doi: 10.1161/01.CIR.101.5.570 |
| [19] |
Herrmann J . Peri-procedural myocardial injury: 2005 update[J]. Eur Heart J, 2005,26(23):2493-2519
doi: 10.1093/eurheartj/ehi455 |
| [20] |
Galiuto L, Garramone B, Burzotta F, Lombardo A, Barchetta S, Rebuzzi AG, Crea F; REMEDIA Investigators . Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA Trial[J]. J Am Coll Cardiol, 2006,48(7):1355-1360
doi: 10.1016/j.jacc.2006.05.059 |
| [21] |
Srinivasan M, Rihal C, Holmes DR, Prasad A . Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes[J]. Circulation, 2009,119(9):1311-1319
doi: 10.1161/CIRCULATIONAHA.108.831453 |
| [22] |
Heusch G, Schulz R, Haude M, Erbel R . Coronary microembolization[J]. J Mol Cell Cardiol, 2004,37(1):23-31
doi: 10.1016/j.yjmcc.2004.04.011 |
| [23] | Lee KW, Norell MS . Management of ‘no-reflow’ complicating reperfusion therapy[J]. Acute Card Care, 2008,10(1):5-14 |
| [24] | Pasceri V, Patti G, Di Sciascio G . Prevention of myocardial damage during coronary intervention[J]. Cardiovasc Hematol Disord Drug Targets, 2006,6(2):77-83 |
| [25] |
Davies MJ, Thomas AC, Knapman PA, Hangartner JR . Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death[J]. Circulation, 1986,73(3):418-427
doi: 10.1161/01.CIR.73.3.418 |
| [26] |
Valero SJ, Moreno R, Reyes RM, Recalde AS, Galeote G, Calvo L, Villate A, Sendón JL . Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions[J]. Cardiovasc Hematol Agents Med Chem, 2008,6(2):125-129
doi: 10.2174/187152508783955079 |
| [27] |
Ivandic BT, Sausemuth M, Ibrahim H, Giannitsis E, Gawaz M, Katus HA . Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention[J]. Clin Chem, 2009,55(6):1171-1176
doi: 10.1373/clinchem.2008.115089 |
| [28] | Xing YN, Yang GJ, Liu SN, Wu B, Xu N . The research outline of blood stasis syndrome in coronary heart disease[J]. Zhongguo Yi Yao Dao Bao, 2009,6(2):5-6 |
| 邢亚楠, 杨冠军, 刘苏宁, 吴蓓, 许宁 . 冠心病血瘀证研究概述[J]. 中国医药导报, 2009,6(2):5-6 | |
| [29] |
Praticò D, Tillmann C, Zhang ZB, Li H , FitzGerald GA.Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice[J]. Proc Natl Acad Sci U S A, 2001,98(6):3358-3363
doi: 10.1073/pnas.061607398 |
| [30] |
Ruggeri ZM . Platelets in atherothrombosis[J]. Nat Med, 2002,8(11):1227-1234
doi: 10.1038/nm1102-1227 |
| [31] |
Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy — Ⅰ: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients[J]. BMJ, 1994,308(6921):81-106
doi: 10.1136/bmj.308.6921.81 |
| [32] | Lardizabal JA, Joshi BK, Ambrose JA . The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a yin-yang paradigm[J]. J Invasive Cardiol, 2010,22(6):284-292 |
| [33] | Libby P . Vascular biology of atherosclerosis: overview and state of the art[J]. Am J Cardiol, 2003,91(3A):3A-6A |
| [34] |
Woods A, Brull DJ, Humphries SE, Montgomery HE . Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6[J]. Eur Heart J, 2000,21(19):1574-1583
doi: 10.1053/euhj.1999.2207 |
| [35] |
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V . Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link[J]. Atherosclerosis, 2000,148(2):209-214
doi: 10.1016/S0021-9150(99)00463-3 |
| [36] |
Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI . Interleukin-18︰interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome[J]. Atherosclerosis, 2005,182(1):135-143
doi: 10.1016/j.atherosclerosis.2005.02.002 |
| [37] | Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A . Protective role of interleukin-10 in atherosclerosis[J]. Circ Res, 1999,85(8):e17-e24 |
| [38] |
Terkeltaub RA . IL-10: an “immunologic scalpel” for atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 1999,19(12):2823-2825
doi: 10.1161/01.ATV.19.12.2823 |
| [39] | Terkeltaub RA.Libby P , Simon DI[J]. Inflammation and thrombosis: the clot thickens, 2001,103(13):1718-1720 |
| [40] |
Martin DM, Boys CW, Ruf W . Tissue factor: molecular recognition and cofactor function[J]. FASEB J, 1995,9(10):852-859
doi: 10.1096/fasebj.9.10.7615155 |
| [41] | Nachman RL . Thrombosis and atherogenesis: molecular connections[J]. Blood, 1992,79(8):1897-1906 |
| [42] |
Rodgers GM . Hemostatic properties of normal and perturbed vascular cells[J]. FASEB J, 1988,2(2):116-123
doi: 10.1096/fasebj.2.2.3277885 |
| [43] |
Zouridakis EG, Schwartzman R, Garcia-Moll X, Cox ID, Fredericks S, Holt DW, Kaski JC . Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression[J]. Eur Heart J, 2001,22(17):1578-1584
doi: 10.1053/euhj.2000.2588 |
| [44] |
Rodeberg DA, Chaet MS, Bass RC, Arkovitz MS, Garcia VF . Nitric oxide: an overview[J]. Am J Surg, 1995,170(3):292-303
doi: 10.1016/S0002-9610(05)80017-0 |
| [45] |
Ulker S , McKeown PP, Bayraktutan U.Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells[J]. Cardiovasc Res, 2002,55(4):830-837
doi: 10.1016/S0008-6363(02)00489-3 |